Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-PSCA CAR-T cell therapy - City of Hope National Medical Center/Mustang Bio

Next Previous
Drug Profile

Anti-PSCA CAR-T cell therapy - City of Hope National Medical Center/Mustang Bio

Alternative Names: Anti prostate stem cell antigen-CAR-T cell therapy - City of Hope Medical Center/Mustang Bio; Autologous Anti-PSCA(dCH2)BBz-CAR T-cells; Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-cells; CAR-T cells - Mustang Bio; MB 105; MB-105 PSCA CAR; PSCA(dCH2)BBzeta-CAR T-cells; PSCA‐targeted CAR T cell therapy

Latest Information Update: 05 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Bladder cancer
  • No development reported Gastric cancer; Glioblastoma; Pancreatic cancer

Most Recent Events

  • 02 Jun 2023 Final adverse events and efficacy data from a phase I trial in Prostate cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 24 May 2023 Phase-I clinical trials in Prostate cancer (In adults, In the elderly, Second-line therapy or greater, Metastatic disease, Late-stage disease) in USA (IV) (NCT05805371)
  • 16 Mar 2023 Anti-PSCA CAR-T cell therapy is still in phase I trials for Prostate cancer in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top